Data protection provisions in CETA

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Data protection provisions in CETA

Genéricos/Investigación | Posted 01/08/2014 0 Post your comment

The trade agreement between the European Union (EU) and Canada has the potential to have a negative affect on the generics industry in Canada [1]. In particular, certain intellectual property provisions are seen as the main culprits.

The data protection provision is one such provision seen as causing harm to the generics industry.

Data protection
In 2006, Canada extended data protection to eight years of market exclusivity with an additional six months if companies have studied the drug in a paediatric population. Generics companies are not allowed to make use of the brand-name companies’ data in their applications for a minimum of six years. The European Union, on the other hand, provides for 10 years of data protection and had been pushing for the same in Canada as part of the Comprehensive Economic and Trade Agreement (CETA).

Although CETA will not extend data protection, Canada has ‘agreed to lock in the current Canadian practice of providing eight years of market exclusivity’, making it virtually impossible for any future government to shorten the period.

The North American Free Trade Agreement (NAFTA) and the TRIPS agreement both specify that data should be protected for five years.

Up until CETA, data protection was only granted to new chemical entities, i.e. drugs that have never been sold in any form in Canada. During the negotiations, the EU was demanding that improved data protection be granted for any pharmaceutical product rather than just new chemical entities.

It is unclear if CETA will extend data protection to include products representing minor changes to an existing drug. If this is the case it is seen as offering a financial incentive to companies to engage in minor molecular manipulation to gain further data protection and produce drugs that offer no new therapeutic advances.

Related articles
Influence of CETA on generics

Patent term restoration provisions in CETA

Reference

1. Lexchin J, Gagnon MA. CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Global Health. 2014;10:30.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.